Cubicin (daptomycin) / Merck (MSD)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

   Remove FilterRemove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cubicin (daptomycin) / Merck (MSD)
2021-003891-15: Clinical trial to evaluate the safety and efficacy of a 7-day versus 14-day treatment for enterococcal infections. Ensayo clínico para evaluar la seguridad y eficacia de un tratamiento de 7 días frente a 14 días para infecciones por enterococos.

Not yet recruiting
4
284
Europe
Ciprofloxacin, ampicilin, vancomycin, linezolid, daptomycin, amoxicillin / clavulanic acid, piperacillin / tazobactam, amoxicilin, Film-coated tablet + pessary, Suspension for injection, Powder and solvent for solution for infusion, Solution for injection/infusion, Powder and solvent for solution for injection/infusion, Film-coated tablet, Tablet, Ciprofloxacin, ampicilin, vancomycin, linezolid, daptomycin, amoxicillin / clavulanic acid, piperacillin / tazobactam, amoxicilin
Fundación Pública Andaluza para la Gestión de la Investigación en Salud de Sevilla (FISEVI), Instituto de Salud Carlos III. Ministerio de Ciencia e Innovación
Adult patients with uncomplicated bacteremia caused by E. faecalis or E. faecium. Pacientes adultos con bacteriemias no complicadas causadas por E. Faecalis o E. faecium., Adult patients with infections that produce the passing of certainbacteria to the bloodstream. Pacientes adultos con infecciones que producen el paso de ciertasbacterias al torrente sanguíneo., Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 

Download Options